Cargando…
Erythrodermic psoriasis improved by Tildrakizumab
Erythrodermic psoriasis (EP), clinically defined as prominent erythema and scaling affecting almost the entire skin surface, is a severe form and a rare variant of psoriasis. The treatment may require hospital admission with monitoring of vital signs and use of immunosuppressive drugs. Newer biologi...
Autores principales: | Trevisan, Giampaolo, Germi, Lerica, Naldi, Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724727/ https://www.ncbi.nlm.nih.gov/pubmed/36483225 http://dx.doi.org/10.4081/dr.2022.9448 |
Ejemplares similares
-
Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021) -
Keratolysis exfoliativa-like eruption induced by ranolazine
por: Pierobon, Elena, et al.
Publicado: (2022) -
Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022) -
Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016) -
The Management of Erythrodermic Psoriasis Complicated by Cyclosporine
por: Rao, Suman, et al.
Publicado: (2020)